Why Space?<br />National Lab Pathfinder Strategy:Applying knowledge from microgravity research to develop medicines in spa...
Resistance to drug treatments
Virulence (Infectious capabilities)</li></ul>Commercial Products:Creation of new vaccines, therapeutics and druggable targ...
Flight Studies & Progress<br /><ul><li>Nine successful spaceflight payloads have been conducted in a 24 month period start...
Flight Studies & Progress<br /><ul><li>Salmonella vaccine target has been identified and is moving towards FDA-IND filings.
MRSA virulence targets have been identifiedand are currently being validated on STS-131.</li></li></ul><li>
Future Opportunities<br /><ul><li>Pipeline with 7 additional microbes has been conducted and manifested on future flights.
Upcoming SlideShare
Loading in …5
×

Developing Medicines in Space to Save Lives on Earth

1,151 views

Published on

Developing Medicines in Space to Save Lives on Earth
by Thomas B. Pickens III
President and CEO, Astrogenetix

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,151
On SlideShare
0
From Embeds
0
Number of Embeds
14
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Developing Medicines in Space to Save Lives on Earth

  1. 1.
  2. 2. Why Space?<br />National Lab Pathfinder Strategy:Applying knowledge from microgravity research to develop medicines in space to save lives on Earth.<br />Advantages of Microgravity:Growth within the space environment induces valuable changes in microbial cells.<br />Commercial Value:These changes provide biomarkers that are associated with: <br /><ul><li>Growth (rate and size)
  3. 3. Resistance to drug treatments
  4. 4. Virulence (Infectious capabilities)</li></ul>Commercial Products:Creation of new vaccines, therapeutics and druggable targets.<br />
  5. 5. Flight Studies & Progress<br /><ul><li>Nine successful spaceflight payloads have been conducted in a 24 month period starting in March 2008, representing unprecedented continuous access for commercial development utilizing microgravity.</li></ul>Date Mission Sample<br />Date Mission Sample<br />05/2009 STS-125 MRSA<br />08/2009 STS-128 MRSA<br />11/2009 STS-129 MRSA<br />02/2010 STS-130 MRSA<br />04/2010 STS-131 MRSA<br />03/2008 STS-123 Salmonella<br />05/2008 STS-124 Salmonella<br />11/2008 STS-126 Salmonella<br />03/2009 STS-119 MRSA<br /> Streptococcus pneumonia<br /> Candida albicans<br /> Proteus mirabilis<br />Klebsiella pneumonia<br />Enterococcusfaecalis<br />Listeriamonocytogenes<br /> Pseudomonas aeruginosa<br />
  6. 6. Flight Studies & Progress<br /><ul><li>Salmonella vaccine target has been identified and is moving towards FDA-IND filings.
  7. 7. MRSA virulence targets have been identifiedand are currently being validated on STS-131.</li></li></ul><li>
  8. 8. Future Opportunities<br /><ul><li>Pipeline with 7 additional microbes has been conducted and manifested on future flights.
  9. 9. Development of valuable therapeutics such as antibiotics.
  10. 10. Protein Crystal Growth identified as a valuable opportunity.
  11. 11. Critical in the development of therapeutics for very complex diseases such as Alzheimer's, Parkinson's, Lou Gehrig's, AIDS, etc.
  12. 12. ISS completion is essential for long-term sustained microgravity crystal growth.</li></li></ul><li>Commercial Growth<br /><ul><li>Given the potential value to mankind, all available ISS National Lab space should be utilized.
  13. 13. Expectations for medical breakthroughs are exceptional and ISS extension to 2020 provides the commitment to explore these opportunities.
  14. 14. The ISS is the only place in existence providing sustained microgravity research opportunities. Our knowledge of the results from removing the effects of gravity has just begun and must continue. </li></li></ul><li>

×